Cardiovascular Genescreen(TM)

What is it?

A DNA test that consists of two components for disease diagnosis and gene-based intervention:

  1. A population-specific familial hypercholesterolaemia (FH) test including 8 gene defects in the LDL receptor gene.
  2. A globally applicable multi-gene cardiovascular disease (CVD) test including 12 mutations in 10 different genes involved in lipid metabolism, folate metabolism, blood clotting and iron overload.

The FH gene test is usually performed in patients with high cholesterol levels and a family history of early-onset coronary heart disease. The CVD multi-gene test is applicable in any person at risk of CVD and related disorders, including venous thrombosis, pregnancy complications, dementia, and inherited iron overload (haemochromatosis). Confirmation or exclusion of FH, irrespective of whether the diagnosis of this lipid disorder is made on the clinical or DNA level, forms the basis of the Cardiovascular Genescreen. The results of the genetic test and the lipid profile  are combined with clinical indicators and lifestyle factors to identify a combination of risk factors that may led to disease development or progression, if left untreated.



Powered by PyroLogic ContentBuilder(c) a Product, Designed and Developed by Dirk Cloete - 8105185012084